IP Library Granted Patent US 9,198,858
Granted Patent B2
US 9,198,858 · App. 13/593,386 · Granted Dec 1, 2015

Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,198,858
App. No.
13/593,386
Granted
Dec 1, 2015
Kind
B2
Abstract

The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.

Claims (15)

1. A method of treating bacterial vaginosis (“BV”) comprising a step of:

administering to a subject suffering from and/or diagnosed with BV a treatment that consists of a single intravaginal administration of an aqueous-based gel composition containing active agent that consists of about 65 mg metronidazole (“MTZ”), wherein the concentration of MTZ is about 1.3% by weight; and the aqueous-based gel is free of dextrins, cyclodextrins, niacin, niacinamide, and surfactants.

2. The method of claim 1 , wherein the step of administering comprises administering a single unit dose of the aqueous-based gel composition, which unit dose contains about 65 mg of MTZ.

3. The method of claim 2 , wherein the aqueous-based gel composition comprises one or more gelling polymers, about 1.3% by weight MTZ, a solvent system for MTZ, and water.

4. The method of claim 3 , wherein the aqueous-based MTZ gel composition comprises about 1.3 wt % MTZ, about 1 wt % to about 3 wt % of one or more gelling polymers, about 30 wt % to about 60 wt % of a solvent system for the MTZ, and about 30 wt % to about 60 wt % water.

5. The method of claim 3 , wherein the solvent system comprises one or more lower aromatic alcohols, one or more lower aliphatic diols and/or one or more polyoxyalkylenes having a molecular weight ranging from about 200 to about 400.

6. The method of claim 5 , wherein the one or more lower aromatic alcohols are selected from the group consisting of benzyl alcohol, phenoxyethanol, and mixtures thereof.

7. The method of claim 5 , wherein the one or more lower aliphatic diols are selected from the group consisting of ethane-1,2-diol (ethylene glycol), propane-1,2-diol(propylene glycol), and mixtures thereof.

8. The method of claim 5 , wherein the one or more lower polyoxyalkylenes are selected from the group consisting of polyoxyethylene (polyethylene glycol), polyoxypropylene (polypropylene glycol), and mixtures thereof.

9. The method of claim 5 , wherein the solvent system consists of benzyl alcohol, propane-1,2-diol and PEG 400.

10. The method of claim 3 , wherein the aqueous-based MTZ gel composition further comprises one or more preservatives, where the one or more preservatives are optionally esters of 4-hydroxy benzoic acid.

11. The method of claim 3 , wherein the aqueous-based MTZ gel composition has a pH in the range about pH 3.0 to about pH 5.0.

12. The method of claim 3 , wherein the aqueous-based MTZ gel composition has a pH of about pH 4.0.

13. The method of claim 3 , wherein the one or more gelling polymers are selected from the group consisting of a hydroxyethylcellulose, a carbomer, a polycarbophil, and mixtures thereof.

14. The method of claim 3 , wherein the aqueous-based MTZ gel composition comprises about 1.3 wt % MTZ, about 2 wt % polycarbophil AA-1, about 2 wt % benzyl alcohol, about 15 wt % propane-1,2-diol, about 25 wt % PEG 400, about 0.02 wt % methyl 4-hydroxybenzoate, and about 0.08 wt % propyl 4-hydroxybenzoate.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: ALLERGAN SALES, LLC
To: CHEMO RESEARCH SL
Reel/Frame 043777/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2016
From: ACTAVIS LABORATORIES UT, INC.
To: ALLERGAN SALES, LLC
Reel/Frame 039857/0661 →
CHANGE OF NAME Recorded Dec 7, 2015
From: WATSON LABORATORIES, INC.
To: ACTAVIS LABORATORIES UT, INC.
Reel/Frame 037223/0393 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2014
From: MEDICIS PHARMACEUTICAL CORPORATION
To: WATSON LABORATORIES, INC.
Reel/Frame 033996/0751 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2014
From: NORDSIEK, MICHAEL T.; BALAJI, KODUMUDI S.
To: MEDICIS PHARMACEUTICAL CORPORATION
Reel/Frame 033331/0021 →
SECURITY AGREEMENT Recorded Apr 24, 2013
From: MEDICIS PHARMACEUTICAL CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC
Reel/Frame 030281/0433 →